SCHEMBL5359948

SCHEMBL5359948

O=C1/C(=N\c2cccc(C(F)(F)F)c2)c2cc(O)ccc2N1c1ccccc1

nearest known ligand 0.78

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
GALR3 O60755 20/20 0.78
HTR4 Q13639 1/20 0.78
DRD5 P21918 2/20 0.53
ADRA1A P35348 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5359954 1.00 GALR3 (0.78) GALR3HTR4DRD5ADRA1A
SCHEMBL8427817 0.94 GALR3 (0.69) GALR3HTR4DRD5ADRA1A
SCHEMBL8452654 0.94 GALR3 (0.69) GALR3HTR4DRD5ADRA1A
SCHEMBL5356357 0.91 GALR3 (0.78) GALR3HTR4DRD5ADRA1A
SCHEMBL5356363 0.91 GALR3 (0.78) GALR3HTR4DRD5ADRA1A
SCHEMBL916932 0.89 GALR3 (0.78) GALR3HTR4DRD5ADRA1A
SCHEMBL916933 0.89 GALR3 (0.78) GALR3HTR4DRD5ADRA1A
SCHEMBL915968 0.88 GALR3 (0.83) GALR3HTR4DRD5ADRA1A
SCHEMBL915969 0.88 GALR3 (0.83) GALR3HTR4DRD5ADRA1A
SCHEMBL8273294 0.88 GALR3 (1.00) GALR3HTR4DRD5ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7166635-B2 3-imino-2-indolones for the treatment of depression and/or anxiety H. LUNDBECK A/S (DK) 2007-01-23 US disclosed
US-7166635-B2 3-imino-2-indolones for the treatment of depression and/or anxiety H. LUNDBECK A/S (DK) 2007-01-23 US disclosed
US-7166635-B2 3-imino-2-indolones for the treatment of depression and/or anxiety H. LUNDBECK A/S (DK) 2007-01-23 US disclosed
US-20050148635-A1 3-imino-2-indolones for the treatment of depression and/or anxiety SYNAPTIC PHARMACEUTICAL CORPORATION 2005-07-07 US disclosed
US-20050148635-A1 3-imino-2-indolones for the treatment of depression and/or anxiety SYNAPTIC PHARMACEUTICAL CORPORATION 2005-07-07 US disclosed
US-20050148635-A1 3-imino-2-indolones for the treatment of depression and/or anxiety SYNAPTIC PHARMACEUTICAL CORPORATION 2005-07-07 US disclosed
US-20040082615-A1 3-Imino-2-indolones for the treatement of depression and/or anxiety H. LUNDBECK A/S (DK) 2004-04-29 US disclosed
US-20040082615-A1 3-Imino-2-indolones for the treatement of depression and/or anxiety H. LUNDBECK A/S (DK) 2004-04-29 US disclosed
US-20040082615-A1 3-Imino-2-indolones for the treatement of depression and/or anxiety H. LUNDBECK A/S (DK) 2004-04-29 US disclosed
WO-2004014854-A1 3-IMINO-2-INDOLONES FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY SYNAPTIC PHARMACEUTICAL CORPORATION (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148635-A1 3-imino-2-indolones for the treatment of depression and/or anxiety GALR3, GALR2, GALR1 GALR3 1/4885HTR4 17/4885DRD5 452/4885
US-20040082615-A1 3-Imino-2-indolones for the treatement of depression and/or anxiety GALR3, GALR2, GALR1 GALR3 1/4885HTR4 13/4885DRD5 365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.